BrainChip Holdings Limited has secured a non-exclusive, worldwide IP license agreement with ASICLAND Co., Ltd., a South Korean semiconductor solutions provider, marking a significant expansion of the company’s go-to-market strategy. The agreement grants ASICLAND rights to integrate BrainChip’s Akida neuromorphic AI intellectual property into system-on-chip designs for multiple customers across edge AI, industrial, automotive, consumer, and Internet of Things applications. This arrangement establishes a new revenue stream for BrainChip while leveraging ASICLAND’s design capabilities and customer relationships to accelerate Akida adoption across previously untapped market segments.
The partnership structure reflects a carefully balanced approach to commercializing neuromorphic technology while maintaining strict IP protection. ASICLAND gains access to evaluation licenses allowing participation in multi-project wafer fabrication runs, through which customers can produce and test prototype chips for evaluation purposes. Upon successful validation, these evaluation licenses convert to production licenses following BrainChip approval and payment of additional fees, enabling customers to manufacture and sell commercial products incorporating Akida technology. Critically, ASICLAND remains prohibited from sublicensing the intellectual property, which constrains its role to system integrator rather than IP distributor, protecting BrainChip’s long-term licensing model and maintaining direct customer relationships.
BrainChip’s financial participation in the arrangement comprises multiple revenue components: upfront evaluation and production license fees charged on a per-customer basis, ongoing volume-based royalties calculated on net sales of licensed products, and optional fees for training, integration services, and software maintenance. While the company currently cannot quantify the agreement’s financial impact, management has indicated that revenue is anticipated to be material over time, suggesting confidence in ASICLAND’s ability to activate multiple customers across its design portfolio. This recurring revenue structure aligns BrainChip’s interests with ASICLAND’s commercial success, creating incentives for both parties to drive adoption.
For investors, the agreement represents validation of Akida technology from an established semiconductor design house operating in competitive Asian markets. ASICLAND’s decision to license neuromorphic IP rather than developing proprietary alternatives signals confidence in BrainChip’s technical differentiation and competitive positioning. The non-exclusive nature of the license suggests BrainChip retains the ability to pursue similar partnerships with other semiconductor companies, potentially multiplying the addressable market for Akida IP. The agreement also demonstrates BrainChip’s evolving business model shift toward IP licensing and royalty revenue, diversifying beyond direct product sales. Investors should monitor the pace at which ASICLAND activates customer engagements and the speed of conversion from evaluation to production licenses, as these metrics will indicate the commercial viability of the partnership and the timing of material revenue realization. The ASX has flagged this announcement as price sensitive and material.
View the full ASX announcement (PDF)
About BrainChip Holdings Limited (ASX: BRN)
BrainChip is an Australian technology company that develops neuromorphic artificial intelligence hardware and software solutions for edge computing applications. The company’s core products include the Akida neuromorphic processor, which mimics the human brain’s neural architecture to deliver ultra-low power AI processing, and MetaTF software for developing and training neural networks. BrainChip serves markets in North America, Europe, Asia, and the Middle East, targeting applications in security, surveillance, autonomous vehicles, and industrial automation.
If you would like to discuss this announcement or how it might affect your portfolio, request a callback or call us on 1300 889 603.
